ARTIS VENTURES MANAGEMENT, L.P.

Thesis

Artis Ventures Management, L.P. is a San Francisco-based venture capital firm founded in 2001, specializing in early-stage investments within the "TechBio" sector, which represents the intersection of technology and biology. The firm's investment thesis, "TechBio®," focuses on companies that utilize frontier technologies such as artificial intelligence (AI), gene editing, synthetic biology, and advanced diagnostics to drive innovation in human health and well-being. They seek to back visionary founders who are developing platform companies with the potential for broad applications across multiple indications and therapeutic pathways. Artis Ventures invests across Seed, Series A, Series B, and Growth stages, typically acting as both a lead and follow investor. Their primary geographic focus is the United States, with a strong emphasis on the San Francisco Bay Area, though they leverage global networks. The firm explicitly avoids pure software companies without a hard science or hardware component, wellness-only ventures lacking therapeutic validation, and companies solely targeting wealthy developed markets. Fund sizes mentioned include a $200 million TechBio II fund closed in December 2023 and another fund with a size of $175 million. Their check size ranges from $50,000 to $25 million, with typical investments up to $40 million for early-stage and seed rounds, and recent deals ranging from $10 million to $70 million.

Related lists

• Seed-stage AI investors
• Series A AI investors
• Series B AI investors